Edgewise Therapeutics joined PPMD for a community webinar on October 18, 2023 to discuss the company’s investigational compound, EDG-5506. Joanne M. Donovan, M.D., Ph.D., Chief Medical Officer at Edgewise, and Alan Russell, Ph.D., Edgewise’s Co-Founder and Chief Scientific Officer, provided an overview of results from the ongoing open-label ARCH study in adults with Becker muscular dystrophy and shared information about Edgewise’s currently enrolling trial, GRAND CANYON, a phase 2 trial for adults living with Becker.

WATCH THE RECORDING

RELATED CONTENT

• EDG-5506 Drug Developement Pipeline page
• Edgewise Therapeutics announces positive topline 12-month data from EDG-5506 ARCH study – June 27, 2023
• Edgewise Therapeutics now enrolling GRAND CANYON study of EDG-5506 in individuals with Becker muscular dystrophy – September 26, 2023
• Becker Education and Engagement Day – An initiative driven by Becker advocates, clinical sites, advocacy groups, and researchers to unite the Becker community, the first Becker Education and Engagement Day (BEED) is taking place on December 2, 2023. Individuals living with Becker and their families are invited to sites across the country to learn about topics relevant to the Becker community, hear the latest research updates, and connect in person with fellow members of the community. Learn more here.